Poor
Not Aligned
Patient Risk:
High
Summary
Most alcohol-specific claims (worsening GI effects, effects on blood glucose, slowed digestion from alcohol, patient-reported symptom intensification, dizziness/fatigue, appetite reduction, binge-drinking amplification, and clinician guidance to avoid alcohol) are not supported by the provided Ozempic label excerpts. Label support is present only for semaglutide-induced delayed gastric emptying and for adverse outcomes that can follow GI volume depletion (AKI) and acute pancreatitis risk generally, but the alcohol-combination causality is not established in the provided label text.
Category Scores
Accurate Statements
Ozempic (semaglutide) delays gastric emptying.
Supported: 7.2 Oral Medications ("OZEMPIC causes a delay of gastric emptying")
Unsupported Statements
Alcohol can worsen the gastrointestinal side effects of GLP-1 receptor agonists.
No support in the provided Ozempic label excerpts for alcohol worsening GI side effects.
Alcohol can affect blood glucose levels in patients taking Ozempic.
No support in the provided Ozempic label excerpts for alcohol-specific effects on blood glucose.
Ozempic reduces appetite.
No support in the provided Ozempic label excerpts for appetite reduction.
Alcohol slows gastric emptying.
No support in the provided Ozempic label excerpts for alcohol affecting gastric emptying in the context of Ozempic.
Combining alcohol with Ozempic can prolong gastrointestinal discomfort.
No support in the provided Ozempic label excerpts for alcohol specifically prolonging GI discomfort when combined with Ozempic.
People report more intense nausea when mixing Ozempic and alcohol than when using the drug alone.
No support in the provided Ozempic label excerpts for patient-reported symptom intensification with alcohol.
People report more intense vomiting when mixing Ozempic and alcohol than when using the drug alone.
No support in the provided Ozempic label excerpts for patient-reported symptom intensification with alcohol.
People report more intense diarrhea when mixing Ozempic and alcohol than when using the drug alone.
No support in the provided Ozempic label excerpts for patient-reported symptom intensification with alcohol.
Some users report stronger dizziness when mixing Ozempic and alcohol.
No support in the provided Ozempic label excerpts for dizziness with alcohol combination.
Some users report stronger fatigue when mixing Ozempic and alcohol.
No support in the provided Ozempic label excerpts for fatigue with alcohol combination.
The official Ozempic prescribing information does not list direct pharmacokinetic interactions between semaglutide and alcohol.
Based on the provided label excerpts, no statement confirming absence of pharmacokinetic interactions with alcohol is supported.
Binge drinking can amplify the appetite reduction and slowed digestion caused by Ozempic.
No support in the provided Ozempic label excerpts for binge drinking amplifying effects.
The combination may result in low blood sugar in insulin-dependent patients.
The provided excerpts support hypoglycemia risk with insulin secretagogues/insulin used with Ozempic, but do not support alcohol as the driver of that risk.
Doctors typically recommend moderating or avoiding alcohol during Ozempic treatment.
No support in the provided Ozempic label excerpts for clinician guidance on alcohol moderation/avoidance.
Contradictions
Important Omissions
No claim addressing label-supported warnings/monitoring that are relevant to GI adverse reactions leading to dehydration/acute kidney injury (e.g., monitor renal function; advise precautions to avoid fluid depletion; report persistent nausea/vomiting/diarrhea).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response makes numerous unsupported alcohol-specific causality claims (GI worsening, symptom intensification, dizziness/fatigue, and blood glucose effects). This could mislead users/clinicians about specific alcohol-related risks not established in the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple alcohol-combination and patient-reported symptom claims are not supported by the provided FDA-approved Ozempic label excerpts; only delayed gastric emptying is directly supported, and AKI/pancreatitis risks are label-supported but not alcohol-specific.
Suggested Improvement
Remove or rewrite alcohol-specific causality and symptom-reporting claims unless the provided label text explicitly supports them. Keep statements limited to label-supported effects (e.g., semaglutide delays gastric emptying; caution with oral medication absorption) and label-supported warnings (e.g., monitor for AKI due to volume depletion from GI reactions; observe for acute pancreatitis symptoms) without attributing them specifically to alcohol.